TickerGuard
Buy Day today: Poor (44) Weak market breadth · major macro event coming up
EXEL

Exelixis Inc

Healthcare · Biotechnology

56.70$ -2.4% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow EXEL
Line item 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-937.5% -380.9% 107.8% 36.6% 48.7% 54.5% 21.2% 27.9% 22.5% 18.2% 32.3% 38.1%
9.5% 3.8% 0.5% 0.3% 0.9% 0.9% 0.9% 0.9% 1.3% 1.4% 1.3% 1.3%
39.8% 59.1% 12.0% 5.3% 5.2% 5.8% 10.6% 8.4% 6.7% 5.8% 4.3% 4.9%
45.8% 74.1% 20.8% 3.8% -24.1% 13.2% 12.5% 13.6% 9.6%
-40.9% -69.5% 118.7% -1.5% -9.3% 6.9% -4.1% -2.7% -0.8% -0.8% -0.6% -8.2%
1.9% 1.2% 0.9% 4.7% 3.9% 1.3% 3.1% 4.5% 8.6% 8.9% 3.1% 1.7%
582.7% 134.7% -112.8% 7.9% -34.9% -60.7% -13.3% -3.0% -32.6% -1.5% -5.4% 15.1%
0.0% 0.0% 0.0% 0.0%
307.0% -1.4% -2.1% -1.5% -0.9% -1.0% -5.1% -2.7% 1.5% -30.1% -30.1% -40.8%
-46.6% -11.8% -0.3% -41.1% 0.0%
260.8% 410.9% 10.3% -37.6% 1.1% 1.3% -2.5% -1.0% 0.0% -29.8% -29.0% -41.8%
-93.9% 164.7% 5.3% 7.0% 14.9% -4.9% 5.3% 23.9% -10.0% -13.1% -2.1% 11.4%
-939.3% -382.1% 106.9% 31.9% 44.8% 53.1% 18.1% 23.5% 13.9% 9.3% 29.2% 36.4%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?